Clinical Edge Journal Scan

Key clinical point: The presence of some bowel symptoms increased the likelihood of being detected with colorectal cancer (CRC); however, 6 out of 10 participants diagnosed with CRC were asymptomatic. Rectal bleeding and change in bowel habits were associated with the detection of CRC.

Major finding: Almost 20.3% of participants screened with sigmoidoscopy had at least 1 symptom. However, almost 60% of individuals diagnosed with CRC were asymptomatic. Rectal bleeding (odds ratio [OR], 4.3; 95% confidence interval [CI], 3.1-6.1) and change in bowel habits (OR, 3.8; 95% CI, 2.4-6.1) were associated with the detection of CRC.

Study details: This was a cross-sectional study of 42,554 participants in the age group of 50-74 years who were invited to a randomized CRC screening trial for screening by either once-only sigmoidoscopy (n=36,059) or fecal immunochemical test (n=6,495).

Disclosures: The study was supported by grants from Norwegian Parliament. KR Randel declared receiving a research grant from the South-Eastern Norway Regional Health Authority. The other authors declared no conflicts of interest.

Source: Schult AL et al. BMJ Open. 2021 Jul 1. doi: 10.1136/bmjopen-2020-048183.

Key clinical point: The presence of some bowel symptoms increased the likelihood of being detected with colorectal cancer (CRC); however, 6 out of 10 participants diagnosed with CRC were asymptomatic. Rectal bleeding and change in bowel habits were associated with the detection of CRC.

Major finding: Almost 20.3% of participants screened with sigmoidoscopy had at least 1 symptom. However, almost 60% of individuals diagnosed with CRC were asymptomatic. Rectal bleeding (odds ratio [OR], 4.3; 95% confidence interval [CI], 3.1-6.1) and change in bowel habits (OR, 3.8; 95% CI, 2.4-6.1) were associated with the detection of CRC.

Study details: This was a cross-sectional study of 42,554 participants in the age group of 50-74 years who were invited to a randomized CRC screening trial for screening by either once-only sigmoidoscopy (n=36,059) or fecal immunochemical test (n=6,495).

Disclosures: The study was supported by grants from Norwegian Parliament. KR Randel declared receiving a research grant from the South-Eastern Norway Regional Health Authority. The other authors declared no conflicts of interest.

Source: Schult AL et al. BMJ Open. 2021 Jul 1. doi: 10.1136/bmjopen-2020-048183.

Key clinical point: The presence of some bowel symptoms increased the likelihood of being detected with colorectal cancer (CRC); however, 6 out of 10 participants diagnosed with CRC were asymptomatic. Rectal bleeding and change in bowel habits were associated with the detection of CRC.

Major finding: Almost 20.3% of participants screened with sigmoidoscopy had at least 1 symptom. However, almost 60% of individuals diagnosed with CRC were asymptomatic. Rectal bleeding (odds ratio [OR], 4.3; 95% confidence interval [CI], 3.1-6.1) and change in bowel habits (OR, 3.8; 95% CI, 2.4-6.1) were associated with the detection of CRC.

Study details: This was a cross-sectional study of 42,554 participants in the age group of 50-74 years who were invited to a randomized CRC screening trial for screening by either once-only sigmoidoscopy (n=36,059) or fecal immunochemical test (n=6,495).

Disclosures: The study was supported by grants from Norwegian Parliament. KR Randel declared receiving a research grant from the South-Eastern Norway Regional Health Authority. The other authors declared no conflicts of interest.

Source: Schult AL et al. BMJ Open. 2021 Jul 1. doi: 10.1136/bmjopen-2020-048183.

Key clinical point: Efficacy of antiepidermal growth factor receptor (EGFR) for treating metastatic colorectal cancer (CRC) differs with primary tumor location, with efficacy being higher with metastatic left-sided colon cancer than with middle/low rectal cancer.

Major finding: Among patients undergoing the first-line anti-EGFR therapy, those with left-sided vsvs middle/low rectal tumor had significantly higher progression-free survival (hazard ratio [HR], 0.67; P = .007), overall survival (HR, 0.62; P = .008), and overall response rate (P = .002). Findings were similar with nonfirst-line anti-EGFR treatment.

Study details: Findings are from a retrospective cohort study of 609 patients with metastatic CRC who were treated with anti-EGFR therapy. Based on primary tumor location, patients were classified into right-sided colon (n=125), left-sided colon (n=313), and the middle/low rectal (n=171) groups.

Disclosures: The study was supported by grants from the Ministry of Science and Technology, Taiwan; Taipei Veterans General Hospital; and the Taiwan Clinical Oncology Research Foundation. The authors declared no competing interests.

Source: Lee KH et al. Br J Cancer. 2021 Jun 29. doi: 10.1038/s41416-021-01470-2.

Key clinical point: Efficacy of antiepidermal growth factor receptor (EGFR) for treating metastatic colorectal cancer (CRC) differs with primary tumor location, with efficacy being higher with metastatic left-sided colon cancer than with middle/low rectal cancer.

Major finding: Among patients undergoing the first-line anti-EGFR therapy, those with left-sided vsvs middle/low rectal tumor had significantly higher progression-free survival (hazard ratio [HR], 0.67; P = .007), overall survival (HR, 0.62; P = .008), and overall response rate (P = .002). Findings were similar with nonfirst-line anti-EGFR treatment.

Study details: Findings are from a retrospective cohort study of 609 patients with metastatic CRC who were treated with anti-EGFR therapy. Based on primary tumor location, patients were classified into right-sided colon (n=125), left-sided colon (n=313), and the middle/low rectal (n=171) groups.

Disclosures: The study was supported by grants from the Ministry of Science and Technology, Taiwan; Taipei Veterans General Hospital; and the Taiwan Clinical Oncology Research Foundation. The authors declared no competing interests.

Source: Lee KH et al. Br J Cancer. 2021 Jun 29. doi: 10.1038/s41416-021-01470-2.

Key clinical point: Efficacy of antiepidermal growth factor receptor (EGFR) for treating metastatic colorectal cancer (CRC) differs with primary tumor location, with efficacy being higher with metastatic left-sided colon cancer than with middle/low rectal cancer.

Major finding: Among patients undergoing the first-line anti-EGFR therapy, those with left-sided vsvs middle/low rectal tumor had significantly higher progression-free survival (hazard ratio [HR], 0.67; P = .007), overall survival (HR, 0.62; P = .008), and overall response rate (P = .002). Findings were similar with nonfirst-line anti-EGFR treatment.

Study details: Findings are from a retrospective cohort study of 609 patients with metastatic CRC who were treated with anti-EGFR therapy. Based on primary tumor location, patients were classified into right-sided colon (n=125), left-sided colon (n=313), and the middle/low rectal (n=171) groups.

Disclosures: The study was supported by grants from the Ministry of Science and Technology, Taiwan; Taipei Veterans General Hospital; and the Taiwan Clinical Oncology Research Foundation. The authors declared no competing interests.

Source: Lee KH et al. Br J Cancer. 2021 Jun 29. doi: 10.1038/s41416-021-01470-2.

Key clinical point: In patients with colorectal peritoneal metastasis (CRPM), survival is closely related to pathological response (PR) ratio to preoperative chemotherapy in patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), with best outcomes observed in patients with complete PR (CPR).

Major finding: The rate of complications was significantly higher in the low PR (LPR; 65.2%) vsvs CPR (55%) and high PR (HPR; 42.8%; P = .03) groups. Disease-free survival was significantly higher in CPR and HPR vsvs LPR groups (P less than .001). Overall survival was significantly higher in CPR vsvs HPR and LPR groups (P = .004).

Study details: Findings are from a retrospective analysis of 178 patients with CRPM who underwent a CRS/HIPEC procedure and had a final completeness of cytoreduction score of 0. Based on the ratio of tumor-positive specimens to the total number of specimens resected, patients were categorized into CPR, HPR, and LPR groups.

Disclosures: The authors did not declare any source of funding. All the authors declared no conflicts of interest.

Source: Mor E et al. Ann Surg Oncol. 2021 Jul 7. doi: 10.1245/s10434-021-10367-6.

Key clinical point: In patients with colorectal peritoneal metastasis (CRPM), survival is closely related to pathological response (PR) ratio to preoperative chemotherapy in patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), with best outcomes observed in patients with complete PR (CPR).

Major finding: The rate of complications was significantly higher in the low PR (LPR; 65.2%) vsvs CPR (55%) and high PR (HPR; 42.8%; P = .03) groups. Disease-free survival was significantly higher in CPR and HPR vsvs LPR groups (P less than .001). Overall survival was significantly higher in CPR vsvs HPR and LPR groups (P = .004).

Study details: Findings are from a retrospective analysis of 178 patients with CRPM who underwent a CRS/HIPEC procedure and had a final completeness of cytoreduction score of 0. Based on the ratio of tumor-positive specimens to the total number of specimens resected, patients were categorized into CPR, HPR, and LPR groups.

Disclosures: The authors did not declare any source of funding. All the authors declared no conflicts of interest.

Source: Mor E et al. Ann Surg Oncol. 2021 Jul 7. doi: 10.1245/s10434-021-10367-6.

Key clinical point: In patients with colorectal peritoneal metastasis (CRPM), survival is closely related to pathological response (PR) ratio to preoperative chemotherapy in patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), with best outcomes observed in patients with complete PR (CPR).

Major finding: The rate of complications was significantly higher in the low PR (LPR; 65.2%) vsvs CPR (55%) and high PR (HPR; 42.8%; P = .03) groups. Disease-free survival was significantly higher in CPR and HPR vsvs LPR groups (P less than .001). Overall survival was significantly higher in CPR vsvs HPR and LPR groups (P = .004).

Study details: Findings are from a retrospective analysis of 178 patients with CRPM who underwent a CRS/HIPEC procedure and had a final completeness of cytoreduction score of 0. Based on the ratio of tumor-positive specimens to the total number of specimens resected, patients were categorized into CPR, HPR, and LPR groups.

Disclosures: The authors did not declare any source of funding. All the authors declared no conflicts of interest.

Source: Mor E et al. Ann Surg Oncol. 2021 Jul 7. doi: 10.1245/s10434-021-10367-6.

Key clinical point: Initial phase 2 results do not support combining pembrolizumab to neoadjuvant chemoradiotherapy after 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) treatment of locally advanced rectal cancer (LARC), despite being safe.

Major finding: The mean neoadjuvant rectal (NAR) score was not significantly different among patients treated with vsvs without pembrolizumab (difference, 2.55; P = .26). Grade 3/4 adverse events were slightly higher in patients receiving pembrolizumab vsvs those not (48.2% vsvs 37.3%).

Study details: Findings are from an open-label, phase 2 trial including 185 patients with stage II/III LARC at high risk for metastatic disease who were eligible for sphincter-sparing surgery. Patients were randomly assigned to receive FOLFOX (6 cycles) followed by chemoradiotherapy with (n=90) or without (n=95) intravenous pembrolizumab for up to 6 doses before surgery.

Disclosures: The study was supported by the National Cancer Institute and Merck. Some of the authors including the lead author reported receiving personal fees, grants, honoraria, and/or serving as a consultant and/or on advisory boards for various sources.

Source: Rahma OE et al. JAMA Oncol. 2021 Jul 1. doi: 10.1001/jamaoncol.2021.1683.

Key clinical point: Initial phase 2 results do not support combining pembrolizumab to neoadjuvant chemoradiotherapy after 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) treatment of locally advanced rectal cancer (LARC), despite being safe.

Major finding: The mean neoadjuvant rectal (NAR) score was not significantly different among patients treated with vsvs without pembrolizumab (difference, 2.55; P = .26). Grade 3/4 adverse events were slightly higher in patients receiving pembrolizumab vsvs those not (48.2% vsvs 37.3%).

Study details: Findings are from an open-label, phase 2 trial including 185 patients with stage II/III LARC at high risk for metastatic disease who were eligible for sphincter-sparing surgery. Patients were randomly assigned to receive FOLFOX (6 cycles) followed by chemoradiotherapy with (n=90) or without (n=95) intravenous pembrolizumab for up to 6 doses before surgery.

Disclosures: The study was supported by the National Cancer Institute and Merck. Some of the authors including the lead author reported receiving personal fees, grants, honoraria, and/or serving as a consultant and/or on advisory boards for various sources.

Source: Rahma OE et al. JAMA Oncol. 2021 Jul 1. doi: 10.1001/jamaoncol.2021.1683.

Key clinical point: Initial phase 2 results do not support combining pembrolizumab to neoadjuvant chemoradiotherapy after 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) treatment of locally advanced rectal cancer (LARC), despite being safe.

Major finding: The mean neoadjuvant rectal (NAR) score was not significantly different among patients treated with vsvs without pembrolizumab (difference, 2.55; P = .26). Grade 3/4 adverse events were slightly higher in patients receiving pembrolizumab vsvs those not (48.2% vsvs 37.3%).

Study details: Findings are from an open-label, phase 2 trial including 185 patients with stage II/III LARC at high risk for metastatic disease who were eligible for sphincter-sparing surgery. Patients were randomly assigned to receive FOLFOX (6 cycles) followed by chemoradiotherapy with (n=90) or without (n=95) intravenous pembrolizumab for up to 6 doses before surgery.

Disclosures: The study was supported by the National Cancer Institute and Merck. Some of the authors including the lead author reported receiving personal fees, grants, honoraria, and/or serving as a consultant and/or on advisory boards for various sources.

Source: Rahma OE et al. JAMA Oncol. 2021 Jul 1. doi: 10.1001/jamaoncol.2021.1683.

Key clinical point: Higher preoperative habitual dietary fiber intake was associated with a lower risk for postoperative complications among patients with colorectal cancer (CRC) who underwent surgery.

Major finding: Higher dietary fiber intake (per 10 grams/day) before surgery was significantly associated with a lower risk for any postoperative complications (odds ratio [OR], 0.75; 95% confidence interval [CI], 0.62-0.92) and surgical postoperative complications (OR, 0.76; 95% CI, 0.60-0.97).

Study details: Findings are from a cohort study of 1,399 adult patients with stages I to IV CRC who underwent elective abdominal surgery.

Disclosures: The study was supported by grants from the Dutch Research Council. M van Zutphen and Dr. de Wilt reported receiving grants from various sources outside the submitted work.

Source: Kok DE et al. JAMA Surg. 2021 Jun 16. doi: 10.1001/jamasurg.2021.2311.

Key clinical point: Higher preoperative habitual dietary fiber intake was associated with a lower risk for postoperative complications among patients with colorectal cancer (CRC) who underwent surgery.

Major finding: Higher dietary fiber intake (per 10 grams/day) before surgery was significantly associated with a lower risk for any postoperative complications (odds ratio [OR], 0.75; 95% confidence interval [CI], 0.62-0.92) and surgical postoperative complications (OR, 0.76; 95% CI, 0.60-0.97).

Study details: Findings are from a cohort study of 1,399 adult patients with stages I to IV CRC who underwent elective abdominal surgery.

Disclosures: The study was supported by grants from the Dutch Research Council. M van Zutphen and Dr. de Wilt reported receiving grants from various sources outside the submitted work.

Source: Kok DE et al. JAMA Surg. 2021 Jun 16. doi: 10.1001/jamasurg.2021.2311.

Key clinical point: Higher preoperative habitual dietary fiber intake was associated with a lower risk for postoperative complications among patients with colorectal cancer (CRC) who underwent surgery.

Major finding: Higher dietary fiber intake (per 10 grams/day) before surgery was significantly associated with a lower risk for any postoperative complications (odds ratio [OR], 0.75; 95% confidence interval [CI], 0.62-0.92) and surgical postoperative complications (OR, 0.76; 95% CI, 0.60-0.97).

Study details: Findings are from a cohort study of 1,399 adult patients with stages I to IV CRC who underwent elective abdominal surgery.

Disclosures: The study was supported by grants from the Dutch Research Council. M van Zutphen and Dr. de Wilt reported receiving grants from various sources outside the submitted work.

Source: Kok DE et al. JAMA Surg. 2021 Jun 16. doi: 10.1001/jamasurg.2021.2311.

Key clinical point: Pituitrin 2 units (2U) for laparoscopic uterine myomectomy could provide a satisfactory surgical field with minimal hemodynamic changes.

Major finding: There were no differences among 2U, 4U, and 6U groups in the surgical condition quality. Pituitrin 2U significantly reduced blood loss vs pituitrin 0U, and increasing the pituitrin dose beyond 2U did not reduce blood loss further.

Study details: In a prospective, double-blind trial, 118 patients undergoing laparoscopic myomectomy were randomly assigned to receive 0U, 2U, 4U, or 6U of pituitrin injected into the myometrium surrounding the myoma.

Disclosures: The study was supported by grants from the National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Guo F et al. J Minim Invasive Gynecol. 2021 Jun 17. doi: 10.1016/j.jmig.2021.06.008.

Key clinical point: Pituitrin 2 units (2U) for laparoscopic uterine myomectomy could provide a satisfactory surgical field with minimal hemodynamic changes.

Major finding: There were no differences among 2U, 4U, and 6U groups in the surgical condition quality. Pituitrin 2U significantly reduced blood loss vs pituitrin 0U, and increasing the pituitrin dose beyond 2U did not reduce blood loss further.

Study details: In a prospective, double-blind trial, 118 patients undergoing laparoscopic myomectomy were randomly assigned to receive 0U, 2U, 4U, or 6U of pituitrin injected into the myometrium surrounding the myoma.

Disclosures: The study was supported by grants from the National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Guo F et al. J Minim Invasive Gynecol. 2021 Jun 17. doi: 10.1016/j.jmig.2021.06.008.

Key clinical point: Pituitrin 2 units (2U) for laparoscopic uterine myomectomy could provide a satisfactory surgical field with minimal hemodynamic changes.

Major finding: There were no differences among 2U, 4U, and 6U groups in the surgical condition quality. Pituitrin 2U significantly reduced blood loss vs pituitrin 0U, and increasing the pituitrin dose beyond 2U did not reduce blood loss further.

Study details: In a prospective, double-blind trial, 118 patients undergoing laparoscopic myomectomy were randomly assigned to receive 0U, 2U, 4U, or 6U of pituitrin injected into the myometrium surrounding the myoma.

Disclosures: The study was supported by grants from the National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Guo F et al. J Minim Invasive Gynecol. 2021 Jun 17. doi: 10.1016/j.jmig.2021.06.008.

Key clinical point: Myomectomy is a cost-effective treatment option for uterine fibroids compared with uterine artery embolization (UAE).

Major finding: UAE was associated with higher mean costs (difference, £645; 95% confidence interval [CI], £−1,381 to £2,580) and lower quality-adjusted life years (difference, −0.09; 95% CI, −0.11 to −0.04) vs myomectomy over a 2-year follow-up period. Results were comparable over a 4-year follow-up period.

Study details: The data come from a cost-utility analysis of the FEMME trial. A total of 254 premenopausal women with symptomatic uterine fibroids were randomly assigned to either UAE (n=127) and myomectomy (n=127).

Disclosures: The study was supported by the National Institute of Health Research Health Technology Assessment programme. The authors declared no relevant conflicts of interest.

Source: Rana D et al. BJOG. 2021 May 30. doi: 10.1111/1471-0528.16781.

Key clinical point: Myomectomy is a cost-effective treatment option for uterine fibroids compared with uterine artery embolization (UAE).

Major finding: UAE was associated with higher mean costs (difference, £645; 95% confidence interval [CI], £−1,381 to £2,580) and lower quality-adjusted life years (difference, −0.09; 95% CI, −0.11 to −0.04) vs myomectomy over a 2-year follow-up period. Results were comparable over a 4-year follow-up period.

Study details: The data come from a cost-utility analysis of the FEMME trial. A total of 254 premenopausal women with symptomatic uterine fibroids were randomly assigned to either UAE (n=127) and myomectomy (n=127).

Disclosures: The study was supported by the National Institute of Health Research Health Technology Assessment programme. The authors declared no relevant conflicts of interest.

Source: Rana D et al. BJOG. 2021 May 30. doi: 10.1111/1471-0528.16781.

Key clinical point: Myomectomy is a cost-effective treatment option for uterine fibroids compared with uterine artery embolization (UAE).

Major finding: UAE was associated with higher mean costs (difference, £645; 95% confidence interval [CI], £−1,381 to £2,580) and lower quality-adjusted life years (difference, −0.09; 95% CI, −0.11 to −0.04) vs myomectomy over a 2-year follow-up period. Results were comparable over a 4-year follow-up period.

Study details: The data come from a cost-utility analysis of the FEMME trial. A total of 254 premenopausal women with symptomatic uterine fibroids were randomly assigned to either UAE (n=127) and myomectomy (n=127).

Disclosures: The study was supported by the National Institute of Health Research Health Technology Assessment programme. The authors declared no relevant conflicts of interest.

Source: Rana D et al. BJOG. 2021 May 30. doi: 10.1111/1471-0528.16781.

Key clinical point: Seroprevalence of herpes simplex virus (HSV)-2 was not associated with incidence and growth of ultrasound-diagnosed uterine fibroids in young African-American women.

Major finding: HSV-2 seropositivity had no significant association with fibroid incidence (adjusted hazard ratio, 0.88; 95% confidence interval [CI], 0.69-1.12) or growth 3.1% (95% CI, −5.8% to 13.0%).

Study details: A cohort study examined the associations of HSV-2 with fibroid incidence and growth among African-American women aged 23-35 years who underwent ultrasound fibroid screening.

Disclosures: This study was supported by the Intramural Research Program of the National Institute of Health, the National Institute of Environmental Health Sciences, and the American Recovery and Reinvestment Act funds designated for the National Institute of Health Research. The authors declared no conflicts of interest.

Source: Moore KR et al. Am J Epidemiol. 2021 May 27. doi: 10.1093/aje/kwab160.

Key clinical point: Seroprevalence of herpes simplex virus (HSV)-2 was not associated with incidence and growth of ultrasound-diagnosed uterine fibroids in young African-American women.

Major finding: HSV-2 seropositivity had no significant association with fibroid incidence (adjusted hazard ratio, 0.88; 95% confidence interval [CI], 0.69-1.12) or growth 3.1% (95% CI, −5.8% to 13.0%).

Study details: A cohort study examined the associations of HSV-2 with fibroid incidence and growth among African-American women aged 23-35 years who underwent ultrasound fibroid screening.

Disclosures: This study was supported by the Intramural Research Program of the National Institute of Health, the National Institute of Environmental Health Sciences, and the American Recovery and Reinvestment Act funds designated for the National Institute of Health Research. The authors declared no conflicts of interest.

Source: Moore KR et al. Am J Epidemiol. 2021 May 27. doi: 10.1093/aje/kwab160.

Key clinical point: Seroprevalence of herpes simplex virus (HSV)-2 was not associated with incidence and growth of ultrasound-diagnosed uterine fibroids in young African-American women.

Major finding: HSV-2 seropositivity had no significant association with fibroid incidence (adjusted hazard ratio, 0.88; 95% confidence interval [CI], 0.69-1.12) or growth 3.1% (95% CI, −5.8% to 13.0%).

Study details: A cohort study examined the associations of HSV-2 with fibroid incidence and growth among African-American women aged 23-35 years who underwent ultrasound fibroid screening.

Disclosures: This study was supported by the Intramural Research Program of the National Institute of Health, the National Institute of Environmental Health Sciences, and the American Recovery and Reinvestment Act funds designated for the National Institute of Health Research. The authors declared no conflicts of interest.

Source: Moore KR et al. Am J Epidemiol. 2021 May 27. doi: 10.1093/aje/kwab160.

Key clinical point: A fifth of clinically stable patients receiving intermittent ulipristal acetate (UPA) treatment for uterine fibroids needed surgery after it was suspended by the European Medicines Agency in March 2020, because of safety concerns.

Major finding: Following the suspension of UPA, 20% of patients receiving intermittent UPA needed surgery and 80% needed other medical treatments.

Study details: The data come from an analysis of 85 women who received intermittent UPA treatment until it was suspended in March 2020.

Disclosures: No funding information was available. The authors declared no conflicts of interest.

Source: Nicolás I et al. Gynecol Endocrinol. 2021 May 28. doi: 10.1080/09513590.2021.1929152.

Key clinical point: A fifth of clinically stable patients receiving intermittent ulipristal acetate (UPA) treatment for uterine fibroids needed surgery after it was suspended by the European Medicines Agency in March 2020, because of safety concerns.

Major finding: Following the suspension of UPA, 20% of patients receiving intermittent UPA needed surgery and 80% needed other medical treatments.

Study details: The data come from an analysis of 85 women who received intermittent UPA treatment until it was suspended in March 2020.

Disclosures: No funding information was available. The authors declared no conflicts of interest.

Source: Nicolás I et al. Gynecol Endocrinol. 2021 May 28. doi: 10.1080/09513590.2021.1929152.

Key clinical point: A fifth of clinically stable patients receiving intermittent ulipristal acetate (UPA) treatment for uterine fibroids needed surgery after it was suspended by the European Medicines Agency in March 2020, because of safety concerns.

Major finding: Following the suspension of UPA, 20% of patients receiving intermittent UPA needed surgery and 80% needed other medical treatments.

Study details: The data come from an analysis of 85 women who received intermittent UPA treatment until it was suspended in March 2020.

Disclosures: No funding information was available. The authors declared no conflicts of interest.

Source: Nicolás I et al. Gynecol Endocrinol. 2021 May 28. doi: 10.1080/09513590.2021.1929152.

Key clinical point: Application of temporary uterine tourniquet may be effective in reducing perioperative bleeding in patients with multiple, large-sized uterine fibroids in close proximity of vascular structures.

Major finding: The tourniquet applied group vs not applied group had more favorable outcomes in terms of hemoglobin drop (P = .019), hematocrit drop (P = .023), transfusion amount (P = .012), operation time (P = .044), and duration of hospitalization (P = .036).

Study details: The data come from a retrospective study involving 84 patients who underwent abdominal myomectomy and were categorized into 2 groups according to the use (n=36) or nonuse (n=48) of a temporary uterine tourniquet.

Disclosures: The study did not receive any financial support. The authors declared no conflicts of interest.

Source: Akbaba E et al. J Turk Ger Gynecol Assoc. 2021 Jun 8. doi: 10.4274/jtgga.galenos.2021.2020.0242.

Key clinical point: Application of temporary uterine tourniquet may be effective in reducing perioperative bleeding in patients with multiple, large-sized uterine fibroids in close proximity of vascular structures.

Major finding: The tourniquet applied group vs not applied group had more favorable outcomes in terms of hemoglobin drop (P = .019), hematocrit drop (P = .023), transfusion amount (P = .012), operation time (P = .044), and duration of hospitalization (P = .036).

Study details: The data come from a retrospective study involving 84 patients who underwent abdominal myomectomy and were categorized into 2 groups according to the use (n=36) or nonuse (n=48) of a temporary uterine tourniquet.

Disclosures: The study did not receive any financial support. The authors declared no conflicts of interest.

Source: Akbaba E et al. J Turk Ger Gynecol Assoc. 2021 Jun 8. doi: 10.4274/jtgga.galenos.2021.2020.0242.

Key clinical point: Application of temporary uterine tourniquet may be effective in reducing perioperative bleeding in patients with multiple, large-sized uterine fibroids in close proximity of vascular structures.

Major finding: The tourniquet applied group vs not applied group had more favorable outcomes in terms of hemoglobin drop (P = .019), hematocrit drop (P = .023), transfusion amount (P = .012), operation time (P = .044), and duration of hospitalization (P = .036).

Study details: The data come from a retrospective study involving 84 patients who underwent abdominal myomectomy and were categorized into 2 groups according to the use (n=36) or nonuse (n=48) of a temporary uterine tourniquet.

Disclosures: The study did not receive any financial support. The authors declared no conflicts of interest.

Source: Akbaba E et al. J Turk Ger Gynecol Assoc. 2021 Jun 8. doi: 10.4274/jtgga.galenos.2021.2020.0242.